Early Indication Clinical Trial Reporting

Example Customer

Pharmaceutical Developer

Data Owner

Contract Research Organizations (CROs) and Research Company

Data Users

Research Company

Type of Data

Patient Health Data, Clinical Trial Data

Summary of Pain Point

No Real-Time data analysis

Blinded studies, in general, prohibit interim analysis

Global trials are subject to different privacy laws

Expensive and time consuming to move and combine data in a centralized location for continuous real-time analysis before study completion

Could miss critical pieces of information if granular patient-level data is not part of the aggregation process

Data needs to be de-identified before publications/analysis

Summary of TripleBlind’s Solution

The “Lot Control Numbers” can be matched using privacy enhancing computation (“blindly”), and placebo/real attribute can be joined to efficacy attributes.

“Blinding” is never compromised, aggregated data can be used for early indication reporting.

Attributes returned are controlled, query is “permitted” beforehand, and audit trails are created.

Efficacy reporting is available during study progression. 

Book A Demo

TripleBlind’s innovations build on well understood principles of data protection. Our innovations radically improve the practical use of privacy preserving technologies, by adding true scalability and faster processing, with support for all data and algorithm types. We support all cloud platforms and unlock the intellectual property value of data, while preserving privacy and enforcing compliance with HIPAA and GDPR.